Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2

Arch Pathol Lab Med. 2003 Apr;127(4):465-9. doi: 10.5858/2003-127-0465-MMDNDO.

Abstract

Background: Previous studies have shown conflicting results regarding the expression of c-Erb-B2 in malignant mesothelioma. Overexpression of the c-erb-B2 gene product in a subset of mesothelioma may have prognostic or therapeutic implications.

Objective: To determine whether malignant mesothelioma demonstrates c-Erb-B2 overexpression and, if so, whether such overexpression correlates with gene amplification.

Methods: Immunohistochemistry, reverse transcription-polymerase chain reaction, and fluorescent in situ hybridization were used to analyze archived tissue from 37 cases of malignant mesothelioma.

Results: Although immunohistochemical staining for c-Erb-B2 was detected in most mesotheliomas, the staining was cytoplasmic and was not consistent between the 2 different primary antibodies used. Moreover, even cases with strong cytoplasmic staining for c-Erb-B2 did not demonstrate increased messenger RNA levels or gene copy numbers compared to cases that demonstrated no staining.

Conclusions: Cytoplasmic immunoreactivity for c-Erb-B2 in mesothelioma does not represent gene overexpression or amplification and may be an immunohistochemical artifact.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal, Humanized
  • Artifacts
  • Cytoplasm / chemistry*
  • Cytoplasm / pathology
  • Gene Amplification / genetics*
  • Gene Dosage
  • Gene Expression Regulation, Neoplastic / genetics*
  • Genes, erbB-2 / genetics
  • Humans
  • Immunohistochemistry
  • Mesothelioma / chemistry
  • Mesothelioma / genetics*
  • Mesothelioma / pathology
  • Prognosis
  • Receptor, ErbB-2 / analysis*
  • Receptor, ErbB-2 / immunology
  • Retrospective Studies
  • Staining and Labeling
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab